This HTML5 document contains 176 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/chebi/
n18http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/pharmgkb/
n25http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/kegg-compound/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00424/identifier/drugbank/
n26http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00424
rdf:type
n3:Drug
n3:description
Hyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine. It is a secondary metabolite of some plants, particularly henbane (Hyoscamus niger.) Hyoscyamine is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, pancreatitis, colic and cystitis. It has also been used to relieve some heart problems, control some of the symptoms of Parkinson's disease, as well as for control of respiratory secretions in end of life care.
n3:group
approved
n3:halfLife
2-3.5 hours
n3:indication
For treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Also used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis.
owl:sameAs
n9:DB00424 n18:DB00424
dcterms:title
Hyoscyamine
adms:identifier
n11:17486 n12:DB00424 n21:PA164776844 n22:Hyoscyamine n23:C02046 n24:D00147
n3:mechanismOfAction
Hyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility.
n3:packager
n6:271B4ACA-363D-11E5-9242-09173F13E4C5 n6:271B4AEA-363D-11E5-9242-09173F13E4C5 n6:271B4AF7-363D-11E5-9242-09173F13E4C5 n6:271B4AF5-363D-11E5-9242-09173F13E4C5 n6:271B4AF6-363D-11E5-9242-09173F13E4C5 n6:271B4AFB-363D-11E5-9242-09173F13E4C5 n6:271B4AFC-363D-11E5-9242-09173F13E4C5 n6:271B4AF9-363D-11E5-9242-09173F13E4C5 n6:271B4AFA-363D-11E5-9242-09173F13E4C5 n6:271B4AFF-363D-11E5-9242-09173F13E4C5 n6:271B4B00-363D-11E5-9242-09173F13E4C5 n6:271B4AFD-363D-11E5-9242-09173F13E4C5 n6:271B4AFE-363D-11E5-9242-09173F13E4C5 n6:271B4AEB-363D-11E5-9242-09173F13E4C5 n6:271B4AEC-363D-11E5-9242-09173F13E4C5 n6:271B4AE8-363D-11E5-9242-09173F13E4C5 n6:271B4AE9-363D-11E5-9242-09173F13E4C5 n6:271B4AEF-363D-11E5-9242-09173F13E4C5 n6:271B4AF8-363D-11E5-9242-09173F13E4C5 n6:271B4AED-363D-11E5-9242-09173F13E4C5 n6:271B4AEE-363D-11E5-9242-09173F13E4C5 n6:271B4B01-363D-11E5-9242-09173F13E4C5 n6:271B4AC9-363D-11E5-9242-09173F13E4C5 n6:271B4AF0-363D-11E5-9242-09173F13E4C5 n6:271B4AC7-363D-11E5-9242-09173F13E4C5 n6:271B4AC8-363D-11E5-9242-09173F13E4C5 n6:271B4AF3-363D-11E5-9242-09173F13E4C5 n6:271B4AF4-363D-11E5-9242-09173F13E4C5 n6:271B4AF1-363D-11E5-9242-09173F13E4C5 n6:271B4AF2-363D-11E5-9242-09173F13E4C5 n6:271B4AC6-363D-11E5-9242-09173F13E4C5 n6:271B4ABE-363D-11E5-9242-09173F13E4C5 n6:271B4AC1-363D-11E5-9242-09173F13E4C5 n6:271B4AC2-363D-11E5-9242-09173F13E4C5 n6:271B4ABF-363D-11E5-9242-09173F13E4C5 n6:271B4AC0-363D-11E5-9242-09173F13E4C5 n6:271B4AD2-363D-11E5-9242-09173F13E4C5 n6:271B4AD3-363D-11E5-9242-09173F13E4C5 n6:271B4AD0-363D-11E5-9242-09173F13E4C5 n6:271B4AD1-363D-11E5-9242-09173F13E4C5 n6:271B4AD6-363D-11E5-9242-09173F13E4C5 n6:271B4AD7-363D-11E5-9242-09173F13E4C5 n6:271B4AD4-363D-11E5-9242-09173F13E4C5 n6:271B4AD5-363D-11E5-9242-09173F13E4C5 n6:271B4AC5-363D-11E5-9242-09173F13E4C5 n6:271B4ACB-363D-11E5-9242-09173F13E4C5 n6:271B4AC3-363D-11E5-9242-09173F13E4C5 n6:271B4AC4-363D-11E5-9242-09173F13E4C5 n6:271B4ACE-363D-11E5-9242-09173F13E4C5 n6:271B4ACF-363D-11E5-9242-09173F13E4C5 n6:271B4ACC-363D-11E5-9242-09173F13E4C5 n6:271B4ACD-363D-11E5-9242-09173F13E4C5 n6:271B4AE2-363D-11E5-9242-09173F13E4C5 n6:271B4AE3-363D-11E5-9242-09173F13E4C5 n6:271B4AE0-363D-11E5-9242-09173F13E4C5 n6:271B4AE1-363D-11E5-9242-09173F13E4C5 n6:271B4AE6-363D-11E5-9242-09173F13E4C5 n6:271B4AE7-363D-11E5-9242-09173F13E4C5 n6:271B4AE4-363D-11E5-9242-09173F13E4C5 n6:271B4AE5-363D-11E5-9242-09173F13E4C5 n6:271B4ADA-363D-11E5-9242-09173F13E4C5 n6:271B4ADB-363D-11E5-9242-09173F13E4C5 n6:271B4AD8-363D-11E5-9242-09173F13E4C5 n6:271B4AD9-363D-11E5-9242-09173F13E4C5 n6:271B4ADE-363D-11E5-9242-09173F13E4C5 n6:271B4ADF-363D-11E5-9242-09173F13E4C5 n6:271B4ADC-363D-11E5-9242-09173F13E4C5 n6:271B4ADD-363D-11E5-9242-09173F13E4C5
n3:synonym
(S)-atropine Hyoscyamin Hyoscyaminum Tropine-L-tropate (-)-Hyoscyamine Daturin Hyoscyamine (S)-(-)-Hyoscyamine Daturine Duboisine Tropine, (-)-tropate [3(S)-Endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (−)-hyoscyamine (-)-Atropine (S)-(−)-hyoscyamine L-Hyoscyamine (−)-atropine L-Tropine Tropate
n3:toxicity
Symptoms of overdose include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. LD<sub>50</sub>=mg/kg(orally in rat)
n19:hasAHFSCode
n20:92-02-00%2A n20:12-08-08
n3:foodInteraction
Take 30 minutes before meals, and at bedtime.
n3:mixture
n13:271B4ABD-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
50%
n3:salt
n3:synthesisReference
Jeffrey Kiel, H. Thomas, Emily Ware, Brady Ware, "Phenolic acid complexes of hyoscyamine and process for preparing the same." U.S. Patent US20060128637, issued June 15, 2006.
n16:hasConcept
n17:M0331322
foaf:page
n15:hyoscyamine.html n25:hyoscy.htm
n3:IUPAC-Name
n4:271B4B22-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B28-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B27-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B24-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B25-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B26-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B38-363D-11E5-9242-09173F13E4C5 n4:271B4B20-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B3A-363D-11E5-9242-09173F13E4C5 n4:271B4B1E-363D-11E5-9242-09173F13E4C5 n4:271B4B21-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B3B-363D-11E5-9242-09173F13E4C5 n4:271B4B1F-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4B3C-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n26:A03BA03
n3:H-Bond-Acceptor-Count
n4:271B4B2E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B2F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B29-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B2A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B2C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B2B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B2D-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed totally and completely by sublingual administration as well as oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
101-31-5
n3:category
n3:containedIn
n5:271B4B02-363D-11E5-9242-09173F13E4C5 n5:271B4B03-363D-11E5-9242-09173F13E4C5 n5:271B4B14-363D-11E5-9242-09173F13E4C5 n5:271B4B15-363D-11E5-9242-09173F13E4C5 n5:271B4B12-363D-11E5-9242-09173F13E4C5 n5:271B4B13-363D-11E5-9242-09173F13E4C5 n5:271B4B05-363D-11E5-9242-09173F13E4C5 n5:271B4B06-363D-11E5-9242-09173F13E4C5 n5:271B4B04-363D-11E5-9242-09173F13E4C5 n5:271B4B09-363D-11E5-9242-09173F13E4C5 n5:271B4B0A-363D-11E5-9242-09173F13E4C5 n5:271B4B07-363D-11E5-9242-09173F13E4C5 n5:271B4B08-363D-11E5-9242-09173F13E4C5 n5:271B4B19-363D-11E5-9242-09173F13E4C5 n5:271B4B1A-363D-11E5-9242-09173F13E4C5 n5:271B4B17-363D-11E5-9242-09173F13E4C5 n5:271B4B18-363D-11E5-9242-09173F13E4C5 n5:271B4B1D-363D-11E5-9242-09173F13E4C5 n5:271B4B1B-363D-11E5-9242-09173F13E4C5 n5:271B4B1C-363D-11E5-9242-09173F13E4C5 n5:271B4B0D-363D-11E5-9242-09173F13E4C5 n5:271B4B0E-363D-11E5-9242-09173F13E4C5 n5:271B4B0B-363D-11E5-9242-09173F13E4C5 n5:271B4B0C-363D-11E5-9242-09173F13E4C5 n5:271B4B11-363D-11E5-9242-09173F13E4C5 n5:271B4B16-363D-11E5-9242-09173F13E4C5 n5:271B4B0F-363D-11E5-9242-09173F13E4C5 n5:271B4B10-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B34-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B36-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B37-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B39-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B33-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B32-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B35-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B23-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B30-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B31-363D-11E5-9242-09173F13E4C5